-
Mashup Score: 3Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Phase III TROPiCS-02 study found that the antibody-drug conjugate sacituzumab govitecan leads to #PFSbenefit over single-agent #chemotherapy in patients with pretreated HR+/HER2-, endocrine-resistant #metastatic breast cancer @UCSFCancer #bcsm #bcher: https://t.co/O98X4mMbLU https://t.co/mUYP7PtRH7
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Phase III TROPiCS-02 study found that the antibody-drug conjugate sacituzumab govitecan leads to #PFSbenefit over single-agent #chemotherapy in patients with pretreated HR+/HER2-, endocrine-resistant #metastatic breast cancer @UCSFCancer #bcsm #bcher: https://t.co/XUzVc7Ym81 https://t.co/2RJVf2bx9t
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this issue’s Musings of a Cancer Doctor, @GeorgeSledge51 covers the most exciting presentation at #ASCO2022: the results of the DESTINY-Breast04 trial of trastuzumab deruxtecan in HER2-low metastatic breast cancer #bcher: https://t.co/zUAGn0Gege https://t.co/Sw04vT6sT0
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this week’s issue, @UpToDate presents “What’s New in Oncology,” including the surveillance of #mentalhealth disorders in #AYA cancer survivors and the use of #chemotherapy and anti-HER2-directed therapy in #bcher patients: https://t.co/CPshHghazP https://t.co/p5gDv75h5n
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this week’s issue, @UpToDate presents “What’s New in Oncology,” including the surveillance of #mentalhealth disorders in #AYA cancer survivors and the use of #chemotherapy and anti-HER2-directed therapy in #bcher patients: https://t.co/CPshHghazP https://t.co/RsNWnVPSs2
-
The Phase III TROPiCS-02 study found that the antibody-drug conjugate sacituzumab govitecan leads to #PFSbenefit over single-agent #chemotherapy in patients with pretreated HR+/HER2-, endocrine-resistant #metastatic breast cancer @UCSFCancer #bcsm #bcher: https://t.co/xtiWkCQAUP https://t.co/qcGmkmrB9V